跳至主要内容
临床试验/ACTRN12611000640909
ACTRN12611000640909尚未招募1 期

A phase II clinical trial of vaccination of stem cell donors with Zostavax to reduce the incidence of herpes zoster in transplant recipients – a pilot study.

MERCK SHARP & DOHME0 个研究点目标入组 20 人开始时间: 2011年6月23日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
50 Years 至 80 Years(—)
性别
All

入选标准

  • Allogeneic HSCT Recipient-donor pair
  • Donor aged 50 years and over
  • Signed informed consent by donor and recipient
  • Recipients undergoing myeloablative or non myeloablative non T cell depleted allogeneic stem cell transplants from HLA identical or 1 HLA antigen mismatched siblings.

排除标准

  • Lack of informed consent
  • Inability to recruit donor and recipient as a pair
  • Autologous transplant
  • Contraindication to Zostavax in donor
  • Donor aged <50 years
  • Recipient VZV IgG negative pre-transplantation
  • Donor VZV IgG negative
  • Pregnancy of donor at randomisation
  • Inability to follow study protocol (donor and recipient)
  • Malignancy or immunosuppression of HSC donor
  • Expected HSCT within 30 to 42 days

研究者

相似试验